Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBP MMR vaccine versus GSK MMR vaccine immunogenicity and safety study in Kenyan infants
PACTR202405741158761Phase 3Not yet recruiting
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jun 2024
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of SIBP MMR Vaccine, measles, mumps, and rubella vaccine and 17D yellow fever vaccine in measles, mumps, rubella and 1 more, sponsored by Shanghai Institute of Biological Products. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
SIBP MMR Vaccinemeasles, mumps, and rubella vaccine17D yellow fever vaccine
03
Conditions
measlesmumpsrubellayellow fever
Beyond the preview
Go deeper on PACTR202405741158761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202405741158761.